profit from every $100 of sales.
$0$100
HCW Biologics
$0.77-3.43% today
-69.0% in 1 year
1-year low $0.771-year high $17.34
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What HCW Biologics sold, what it kept, and what it did with the cash.
Sales went from $6.72 million in 2022 to $54,232 in 2025, with -$7.96 million of profit last year.
SalesProfit
HCW Biologics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| HCW Biologics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads HCW Biologics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 7 | 3 | 3 | 0 | |
| 3 | 1 | 1 | 0 | |
| -15 | -26 | -28 | -11 | |
| -14 | -24 | -28 | -6 | |
| -15 | -25 | -30 | -8 | |
| -16.80 | -28.00 | -30.80 | -10.63 | |
| 38.5% | 19.7% | 37.4% | 20.0% | |
| -224.3% | -905.0% | -1,076.4% | -20,757.6% | |
| -221.7% | -879.5% | -1,169.7% | -14,677.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 47 | 29 | 30 | 25 |
| Cash | 22 | 4 | 5 | 2 |
| Total debt | 6 | 6 | 14 | 7 |
| Total liabilities | 9 | 15 | 37 | 22 |
| 37 | 13 | -7 | 3 | |
| 1 | 1 | 1 | 2 | |
| -26.6% | -98.8% | -329.2% | -55.4% | |
| -39.8% | -185.7% | 443.5% | -287.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -10 | -23 | -14 | -13 | |
| 10 | 6 | 0 | – | |
| -21 | -29 | -14 | -13 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 0.3×
- 31.9×
- –
- –
- -774.6%
- -460.4%
- 0.0%
Profitability
- 20.0%
- -20,757.6%
- -14,677.1%
- -10,518.9%
- -113.6%
- -140.5%
- 400.2%
- -32.5%
- -337.4%
- 9,823.6%
Growth
- −79.9%
- –
- +7.6%
- –
- −50.8%
Financial health
- –
- 2.46
- 27.8%
- -13.9×
- 0.11
- 0.11
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 868
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | 0.37 | -0.44 | +184.1% |
| Mar 31, 2026 | -2.63 | -0.84 | −213.1% |
| Nov 14, 2025 | -2.02 | 1.58 | −227.8% |
| Aug 18, 2025 | -6.79 | 1.80 | −477.2% |
| May 15, 2025 | -0.05 | – | – |
| Mar 28, 2025 | -3.20 | 3.60 | −188.9% |
| Nov 14, 2024 | -4.00 | -5.20 | +23.1% |
| Aug 14, 2024 | -16.00 | -7.20 | −122.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
40No pass
Philip Fisher
43No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
27No pass
Questions about HCW Biologics
Is HCW Biologics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the HCW Biologics AI analysis
What does HCW Biologics do?
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. It is in Biotechnology.
Does HCW Biologics pay a dividend?
No. HCW Biologics does not pay a dividend at the moment.
Is HCW Biologics stock halal?
No. HCW Biologics does not pass our halal screen: its debt is 394% of its market value, at or above the 33% limit. How we check
How has HCW Biologics stock done over the past year?
Down 69.0% over the past twelve months, to $0.77. It traded between $0.77 and $17.34 and is 95.5% below its high.
Who are HCW Biologics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with HCW Biologics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.